RVMDW — Revolution Medicines, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1628171 ·
Last close
—
Market Cap
—
52W High
—
52W Low
—
ADV30
—
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -445,222,000 | -453,816,000 | 2,253,737,000 | 440,939,000 | 753,820,000 |
| Dec 2025 | 0 | — | -361,626,000 | -364,892,000 | 2,354,508,000 | 383,745,000 | 723,211,000 |
| Sep 2025 | 0 | — | -315,269,000 | -305,206,000 | 2,251,920,000 | 217,442,000 | 655,016,000 |
| Jun 2025 | 0 | — | -264,714,000 | -247,787,000 | 2,429,568,000 | 402,438,000 | 564,199,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-897,741,000
Investing CF
$118,058,000
Financing CF
$621,524,000
CapEx
$-15,990,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
—
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-2,869,102,000
Inventory
—
Receivables
$0
ST Investments
$1,641,934,000
EBIT TTM
$-1,152,208,000
Pretax Income TTM
$-1,131,301,000
Interest Exp TTM
$23,364,000
Analysts
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -1,182,369,000 | -1,131,301,000 | 2,354,508,000 | 723,211,000 | — | -897,741,000 |
| Dec 2024 | 0 | -689,524,000 | -600,093,000 | 2,558,301,000 | 293,097,000 | — | -557,436,000 |
| Dec 2023 | 11,580,000 | -487,185,000 | -436,367,000 | 2,061,705,000 | 235,511,000 | — | -350,572,000 |
| Dec 2022 | 35,380,000 | -258,279,000 | -248,705,000 | 811,930,000 | 126,742,000 | — | -224,401,000 |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| AMGN | AMGEN INC | $184.40B | $341.66 | — |
| GILD | GILEAD SCIENCES, INC. | $155.75B | $125.45 | — |
| ARGX | ARGENX SE | $55.49B | $892.26 | — |
| RVMD | Revolution Medicines, Inc. | $33.54B | $157.77 | — |
| BIIB | BIOGEN INC. | $29.33B | $198.67 | — |
News headlines (Yahoo Finance, 1h cache)
Pancreatic Cancer Drug Milestone Affirms Why Revolution Medicines Inc. (RVMD) is a Hot Stock to Buy
2026-06-13 19:30 · Yahoo
Daraxonrasib’s Phase 3 Pancreatic Cancer Survival Data Might Change The Case For Investing In RVMD
2026-06-12 00:23 · Yahoo
Can Revolution Medicines Be a Game-Changer Stock?
2026-06-11 11:05 · Yahoo
TNGX Stock Jumps 53% on Early Pancreatic Cancer Study Results
2026-06-09 16:44 · Yahoo
Tango Therapeutics stock surges on pancreatic cancer trial data
2026-06-09 13:31 · Yahoo
Tango Skyrockets On Eye-Popping Pancreatic Cancer Results
2026-06-08 20:05 · Yahoo
Top Midday Gainers
2026-06-08 17:58 · Yahoo
Erasca (ERAS) Is Down 13.4% After IP Challenge to ERAS-0015 Trade Secrets and Patents
2026-06-08 16:12 · Yahoo
Is Revolution Medicines (RVMD) The Best Biotech Stock According to Billionaire Stanley Druckenmiller?
2026-06-08 14:23 · Yahoo
Tango data add to growing momentum for pancreatic cancer drugs
2026-06-08 12:13 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.